Samantha Truex

Biography

Ms. Truex has lead drug development and corporate development activities in multiple companies over more than 20 years in the biotech industry.   Most recently, she served as COO for Synlogic, leading a reverse merger that transformed Synlogic from a private to a public company.  She was CBO for Padlock Therapeutics, where she was integral to Padlock's operations and led the business development process culminating in acquisition by Bristol-Myers Squibb.  Prior to Padlock, Sam spent several years each at Biogen and Genzyme.  At Biogen, Sam served as Vice President of Corporate Development, leading negotiations of multiple licensing, collaboration and acquisition transactions and serving as program executive of FAMPYRA®, ELOCTATE™ and ALPROLIX™. Ms. Truex  earned a BA in biology from Dartmouth College, a BE in biomedical engineering from the Thayer School at Dartmouth and an MBA from the Tuck School at Dartmouth.   She serves on the board of the Thayer School of Engineering and the scientific advisory board for Fondazione Telethon.

Research Interest

Genetics